论文部分内容阅读
本文报告3例在PUVA治疗期间出现的与剂量有关的暂时性视野缺损.例1,女,50岁.患银屑病已35年,1978年6月接受PUVA治疗;1981年12月,当8-甲氧补骨脂素(8-MOP)剂量增加到每周2次,每次40mg时,出现恶心和畏光,并有中心暗点持续达20分钟.开始每天发生约3次,但当剂量降为每周2次,每次20mg时,发作次数减至每周约2次;若每周服药一次20mg时仅偶尔发生;每周一次10mg则不发生;当增加补骨脂素量激发时,视野缺损又可再现.例2,女,25岁.自4岁起患银屑病,于1982年3月接受PUVA治疗;当8-MOP剂量增加到每周2次,每次30mg时,出现恶
This article reports on 3 dose-related temporary visual field defects that occurred during treatment with PUVA Example 1 Female, 50 years old Psoriasis has been 35 years and in June 1978 PUVA was treated; in December 1981, when 8 - The dose of methoxypsoralen (8-MOP) was increased to twice a week with 40 mg each for nausea and photophobia with a central dark spot lasting 20 minutes beginning about 3 times daily, The dose was reduced to 2 times a week, each time the 20mg, the number of seizures reduced to about 2 times per week; weekly medication once only 20mg occasionally; weekly 10mg does not occur; when the increase in psoralen amount of excitation Case 2, female, 25 years old with psoriasis since age 4 and treated with PUVA in March 1982. When the 8-MOP dose was increased to twice a week for 30 mg each , Appear evil